Management of Adrenal Adenoma with Elevated Renin and Low Aldosterone-to-Renin Ratio
This patient does NOT have primary aldosteronism and does not require surgical intervention for the adenoma based on the current biochemical profile. The elevated plasma renin activity (8.58 ng/mL/h) with a low aldosterone-to-renin ratio (0.5) effectively excludes autonomous aldosterone production 1.
Key Diagnostic Interpretation
Your patient's biochemical results demonstrate the opposite pattern of primary aldosteronism:
- Elevated renin (8.58 ng/mL/h, reference 0.25-5.82): This indicates appropriate renin activation, likely secondary to the diuretic therapy (furosemide) and ARB (losartan) she is receiving
- Low ARR (0.5, reference 0.9-28.9): This definitively excludes primary aldosteronism, which requires an elevated ARR (>20-30 depending on units) 1
Critical caveat: Both losartan and furosemide significantly interfere with aldosterone-renin testing 2, 3, 4. Losartan (an ARB) and furosemide both stimulate renin release, which can mask primary aldosteronism by artificially lowering the ARR 2, 3. However, in this case, the pattern is so clearly opposite to PA that it remains interpretable.
Required Next Steps
1. Screen for Autonomous Cortisol Secretion
Perform a 1-mg overnight dexamethasone suppression test immediately 5. This is mandatory for all patients with adrenal adenomas, regardless of aldosterone status 1, 5. The 2025 Endocrine Society guidelines specifically recommend this in all individuals with PA and an adrenal adenoma, and the 2009 AACE/AAES guidelines mandate cortisol screening for all adrenal incidentalomas 1, 5.
2. Exclude Pheochromocytoma
Measure plasma fractionated metanephrines and normetanephrines 5. This is essential before any consideration of intervention.
3. Characterize the Adenoma Radiographically
If not already done, obtain adrenal CT with unenhanced imaging to assess Hounsfield units. Benign adenomas typically show <10 HU on unenhanced CT 5.
Surgical Indications for This Patient
Surgery would be indicated ONLY if:
- The adenoma is ≥4 cm (consider resection due to malignancy risk) 5
- Autonomous cortisol secretion is confirmed (cortisol >5.0 µg/dL post-dexamethasone with clinical consequences) 5
- Pheochromocytoma is diagnosed 5
- Radiographic features suggest malignancy 5
- The mass grows >1 cm on surveillance imaging 5
Management of Hypertension
Continue current antihypertensive therapy with losartan and furosemide, as this is appropriate for essential hypertension. The elevated renin indicates her renin-angiotensin system is appropriately activated, making ARB therapy physiologically sound 3.
If you need to definitively exclude PA for academic purposes (though the current results already do), you would need to:
- Withdraw losartan for 2-4 weeks (substitute with non-interfering agents like verapamil or hydralazine)
- Withdraw furosemide for at least 4 weeks
- Correct any hypokalemia
- Repeat ARR testing 1, 4
However, this is not clinically necessary given the current biochemical profile strongly excludes PA.
Surveillance Protocol
If the adenoma is nonfunctioning and <4 cm:
- Repeat CT at 3-6 months, then annually for 1-2 years 5
- Repeat hormonal evaluation annually for 5 years (dexamethasone suppression test, plasma metanephrines) 5
- Consider repeat ARR testing off interfering medications if clinical suspicion changes
Why This Patient Doesn't Have Primary Aldosteronism
Recent evidence shows that even normotensive patients with adrenal incidentalomas can have subtle aldosterone dysregulation 6, 7. However, your patient's profile shows:
- Activated, not suppressed, renin (the hallmark of PA is suppressed renin <1.0 ng/mL/h) 1, 6
- Low ARR (PA requires elevated ARR, typically >20-30) 1, 8
- Appropriate physiologic response to her medications 2, 3
The 2025 Endocrine Society guidelines emphasize that PA diagnosis requires both elevated aldosterone AND suppressed renin, manifesting as an elevated ARR 1. Your patient has neither.